Identification of Potent and Selective Inhibitors of Acanthamoeba: Structural Insights into Sterol 14α-Demethylase as

Tatiana Y Hargrove1, David C Lamb2, Zdzislaw Wawrzak3

  • 1Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.

PubMed

Insights

Acanthamoeba infections require new drugs. Researchers studied Acanthamoeba sterol 14α-demethylase (CYP51) and found azole drugs like VT1161 show strong inhibition, aiding new treatment development.

Area of Science:

  • Biochemistry
  • Parasitology
  • Structural Biology

Background:

  • Acanthamoeba causes severe infections like keratitis and encephalitis.
  • Developing safe and effective drugs against Acanthamoeba is a critical need.
  • Antifungal azoles have been explored for amoebic infections, but their direct enzyme inhibition is unstudied.

Purpose of the Study:

  • To characterize the catalytic properties and inhibition of Acanthamoeba castellanii sterol 14α-demethylase (CYP51).
  • To determine the structural basis for inhibitor binding to A. castellanii CYP51.
  • To evaluate the potential of repurposed azoles as amoebicidal agents.

Main Methods:

  • Enzyme kinetics assays to determine substrate preference and inhibition constants.
  • Crystallography to obtain the structures of A. castellanii CYP51 with and without inhibitors.
  • Structure-based drug design principles.

Main Results:

  • A. castellanii CYP51 shows a 100-fold preference for obtusifoliol over lanosterol, indicating a plant-like sterol pathway.
  • Voriconazole, VT1598, and VT1161 demonstrated potent inhibition of CYP51 activity.
  • Crystal structures revealed inhibitor binding modes, providing a basis for scaffold development.

Conclusions:

  • Repurposed azoles, particularly VT1161, show significant promise for treating Acanthamoeba infections.
  • Structural insights into A. castellanii CYP51 facilitate the design of novel amoebicidal drugs.
  • Targeting CYP51 is a viable strategy for developing new therapies against blinding and fatal amoebic diseases.

Related Concept Videos

Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...